BioHarvest to join 38th Annual Roth Conference

BioHarvest Sciences Inc. filed a Form 6-K to share a news release announcing that its management has been invited to participate in the 38th Annual Roth Conference for growth companies, held on March 22-24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point.

Rhea-AI Filing Summary

BioHarvest Sciences Inc. filed a Form 6-K to share a news release announcing that its management has been invited to participate in the 38th Annual Roth Conference for growth companies, held on March 22-24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point.

CEO Ilan Sobel will host one-on-one meetings with institutional investors during the event. Sobel highlighted that a successful Q4 2025 financing round left the company fully funded from a near-term capital expenditure perspective and focused on accelerating growth in both its CDMO and consumer product businesses.

The release notes that BioHarvest has over 85,000 direct customers on the product side and anchor CDMO research partnerships, supporting its goal of achieving significant growth milestones in 2026 using its patented Botanical Synthesis technology to develop plant-based compounds.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioHarvest Sciences (BHST) announce in its March 2026 Form 6-K?

BioHarvest Sciences announced its participation in the 38th Annual Roth Conference on March 22-24, 2026. The company will hold one-on-one meetings with institutional investors and emphasized its growth focus following a Q4 2025 financing round.

When and where is BioHarvest Sciences (BHST) attending the 38th Annual Roth Conference?

BioHarvest Sciences will attend the 38th Annual Roth Conference from March 22-24, 2026. The event is being held at The Ritz-Carlton Laguna Niguel in Dana Point, with the company scheduled for one-on-one investor meetings.

What growth positioning did BioHarvest Sciences (BHST) highlight in this update?

BioHarvest highlighted that its Q4 2025 financing round left it fully funded from a near-term CapEx perspective. Management stated the company is focused on accelerating growth in its CDMO and consumer product businesses with significant growth milestones targeted for 2026.

How many direct customers does BioHarvest Sciences (BHST) report on its product side?

BioHarvest Sciences reports having over 85,000 direct customers on its product side. This customer base, combined with anchor CDMO research partnerships, is presented as a foundation for pursuing significant growth milestones in 2026 using plant-based compound innovations.

What is BioHarvest Sciences’ (BHST) core technology and business model?

BioHarvest Sciences uses a patented Botanical Synthesis technology to grow plant-based compounds without cultivating the whole plant. It operates in two verticals: CDMO services for novel plant-based compounds and proprietary nutraceutical health and wellness products, including dietary supplements.

Who will represent BioHarvest Sciences (BHST) at the Roth Conference and in what format?

CEO Ilan Sobel will represent BioHarvest Sciences at the Roth Conference. He is scheduled to conduct one-on-one meetings with institutional investors throughout the event, providing an opportunity to present the company’s story and strategic growth priorities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 02:58 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission file number: 001-42389

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SUBMITTED HEREWITH

Exhibits:

Exhibit	Description
99.1	News Release dated March 3, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOHARVEST SCIENCES INC.
	(Registrant)
Date: March 3, 2026	/s/ David Ryan
	Name: David Ryan
	Title: Vice-President, Investor Relations & Secretary

BioHarvest Sciences to Participate in 38th Annual Roth Conference on March 22-24, 2026

Vancouver, British Columbia and Rehovot, Israel – March 3, 2026– BioHarvest Sciences Inc.,  (“BioHarvest” or the “Company”) (NASDAQ: BHST), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 38th Annual Roth Conference taking place on March 22-24, 2026.

CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event.

38th Annual Roth Conference for Growth Companies

Date: March 22-24, 2026

Location: The Ritz-Carlton Laguna Niguel – Dana Point, CA

Format: 1x1 Meetings

Sobel said: “I am pleased to announce our invitation to the 38th Annual Roth Conference, which is a high-profile opportunity to highlight the BioHarvest story for a select group of sophisticated investors. Our successful Q4 2025 financing round has us at an important inflection point, as we are now fully funded from a near-term CapEx perspective, and focused on driving accelerated growth in both our CDMO and Consumer Product businesses. With now over 85,000 direct customers on our Product side, and anchor CDMO research partnerships, we are well positioned to achieve significant growth milestones in 2026, leveraging novel plant-based compounds in our mission to improve human health and wellness.”

Registration is mandatory for conference participation. For more information or to schedule a meeting with management, please contact info@bioharvest.com.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement

disclosures other than through our regular management discussion and analysis disclosures.

This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.

BioHarvest Corporate Contact:

Dave Ryan, VP Investor Relations

(604) 622-1186

info@bioharvest.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 NEWS RELEASE DATED MARCH 3, 2026 8.3 KB